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ABSTRACT
Studies have investigated biguanide-derived agents for the treatment of cancers 
and have reported their effects against tumorspheres (TSs). The purpose of this study 
was determining the effects of HL156A, a newly designed biguanide with improved 
pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of 
this drug as a new line of therapy against glioblastoma, alone or combined with a 
conventional therapeutic agent, temozolomide(TMZ). The effects of HL156A, alone and 
combined with TMZ, on the stemness and invasive properties of GBM TSs and survival 
of orthotopic xenograft animals were assessed. HL156A, combined with TMZ, inhibited 
the stemness of GBM TSs, proven by neurosphere formation assay and marker 
expression. Three-dimensional collagen matrix invasion assays provided evidence 
that combined treatment inhibited invasive properties, compared with control and 
TMZ-alone treatment groups. TMZ alone and combined treatment repressed the 
expression of epithelial-mesenchymal transition-related genes. A gene ontology 
comparison of TMZ and combination-treatment groups revealed altered expression 
of genes encoding proteins involved in cellular adhesion and migration. Combined 
treatment with HL156A and TMZ showed survival benefits in an orthotopic xenograft 
mouse model. The inhibitory effect of combination treatment on the stemness and 
invasive properties of GBM TSs suggest the potential usage of this regimen as a novel 
strategy for the treatment of GBM.
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INTRODUCTION
Glioblastoma (GBM) is the most aggressive 
malignant brain tumor, with patients showing a very 
limited survival rate despite the best treatment [1]. 
According to National Comprehensive Cancer Network 
(NCCN) guidelines on central nervous system cancer, 
only a third of GBM patients survive for 1 year and less 
than 5% live beyond 5 years [2]. Temozolomide (TMZ), 
an alkylating (methylating) agent, is now the standard of 
care in conjunction with postoperative radiation therapy 
for younger, good-responding patients with GBM [1, 
2]. However, the disease is invariably fatal, and patients 
ultimately succumb because of disease relapse. A 
growing body of evidence supports the idea that cancers 
are initiated and maintained by a subpopulation of cells 
termed cancer stem cells (CSCs) [3, 4]. The clinical 
implication of research on tumor-derived, CSC-enriched 
tumorspheres (TSs) is that a curative therapy will require 
complete elimination of this unique population, even in 
patients with an initial positive response to treatment, 
since the disease may ultimately recur if even a small 
number of CSCs survive the therapy [5, 6]. Accumulating 
evidence has established that CSC populations are more 
resistance to conventional cancer therapy than non-CSC 
populations [7]. For example, CD133-positive GBM 
TSs display a strong capacity to resist chemotherapy 
and radiotherapy [8, 9]. Consequently, novel therapeutic 
strategies designed to eliminate or inhibit CSCs, including 
targeting surface markers or signaling cascades, or altering 
the microenvironment in which these cells potentially 
reside, have been explored [10].
Studies on the biguanide derivate, metformin 
(N’,N’-dimethylbiguanide), the most widely used oral 
therapeutic agent for lowering blood glucose concentration 
in patients with type 2 diabetes, have revealed that 
this agent significantly reduces cancer incidence and 
improves cancer patients’ survival. Laboratory evidence 
of the antineoplastic effects of biguanide has continued 
to accumulate, and results of the first generation of 
clinical trials on metformin are anticipated [11, 12]. A 
number of mechanisms have been suggested to account 
for the direct actions of biguanides on transformed cells 
or cells at risk for transformation, including induction 
of energetic stress and consequent disruption of cellular 
homeostasis, energy depletion caused by inhibition of 
oxidative phosphorylation (OXPHOS), which leads to an 
energy-conserved state, and activation of intracellular 5' 
AMP-activated protein kinase (AMPK), but the precise 
mechanism is still under investigation. Remarkably, Hirsch 
et al. have demonstrated that mass-forming, self-renewing, 
tumor-initiating breast cancer cells exhibit an exaggerated 
sensitivity to metformin [13]. This group suggested that 
transforming growth factor (TGF)-β–induced epithelial-
mesenchymal transition (EMT) might represent a common 
molecular mechanism underlying the anti-CSC actions of 
metformin [11]. However, supporting evidence for this 
concept is still limited. Metformin has limitations as an 
anticancer drug because its hydrophilic nature prevents 
it from entering cells [14]. In addition, metformin only 
enters cells through members of the organic cation 
transporter (OCT) family, whose expression is dependent 
on the genetic background of individuals [14].
HL156A is a derivative of metformin with increased 
hydrophobicity developed by HanAll Biopharma in 
Korea., but its potency and pharmacokinetic property 
were improved [15]. The compounds were evaluated 
the potency of inhibiting OXPHOS in mitochondria 
and pharmacokinetic property in vivo [15]. The toxicity 
of HL156A was assessed and there were no meaningful 
toxicities with up to a 120 mg/kg dose [15]. It was reported 
that HL156A is protective against peritoneal fibrosis in an 
in vitro and in vivo model of peritoneal fibrosis [15].
In the present study, we assessed the effects of the 
newly designed biguanide, HL156A, alone and combined 
with the conventional chemotherapeutic agent TMZ, on 
the tumorsphere properties and survival of orthotopic 
xenografted animals. Our results suggest the feasibility of 




The self-renewal capacity was confirmed in GSC11, 
TS15-88, TS13-20, U87 sphere, and X01 sphere igure 1A). 
Immunocytochemistry revealed that all four cell tyspes 
were positive for CD133 (also known as PROM1), and 
GSC11, TS15-88 and U87 spheres were also positive for 
nestin. Musashi expression was variable, with only GSC11 
and X01 TSs showing partial expression. Podoplanin 
(PDPN) expression was observed only in GSC11 TSs 
(Figure 1B). Neuroglial cells were identified in all GBM-
TSs, as evidenced by the expression of glial fibrillary acidic 
protein (GFAP), major basic protein (MBP), NeuN and/
or TUBB3 (Figure 1C). GFAP and MBP expression was 
not identified in U87 sphere. GFAP and MBP expression 
were not detected in sphere-cultured U87 cells. The 
molecular characteristics of GBM-TSs, including molecular 
subtype based on expression profiles, methylation of the 
O(6)-methylguanine-DNA methyltransferase (MGMT) 
gene promoter and the presence of IDH mutations, are 
summarized in Table 1. An analysis of the gene expression 
profile of these GBM-TSs by microarrays and unsupervised 
clustering revealed that X01 and U87 spheres showed an 
expression profile distinct from that of GSC11 and TS15-88 
TSs, as well as TS13-20 TSs (Figure 1D).
Chemical structure of HL156A and in vivo 
blood-brain barrier permeability
The chemical structure of HL156A (N-[N-{4-
(trifluoromethoxy) phenyl} carbamimidoyl] pyrrolidine-
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Figure 1: Glioblastoma tumorspheres with marker expression of stemness and neuroglial differentiation. A. GSC11, 
TS15-88 and TS13-20 GBM-TSs, and sphere-cultured U87 and X01 cells. B. Expression of stemness markers in GBM-TSs. All GBM 
TSs express all or some stemness markers. C. Neuroglial differentiation of GBM-TSs. D. Unsupervised clustering of gene expression of 
GBM-TSs.
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1-carboximidamide acetate), a derivative of biguanide 
with improved bioavailability, is depicted in Figure 2A. 
In contrast to metformin with limited brain-blood barrier 
permeability due to the heterogenous expression between 
the individuals, HL156A enters the cell independent of 
OCT1 and penetrates extensively into the brain. HL156A 
is cell membrane permeable and orally available in vivo. 
Following oral administration (30 mg/kg) to test mice, the 
brain-to-plasma (BP) ratio of HL156 (0.37) was higher 
than that of metformin (0.10) and phenformin (0.13), 
and its bioavailability was ~72.9%, revealing improved 
penetration into the central nervous system (Figure 2B, 
Table 2 and Supplementary Table 1).
Selection of HL156A and TMZ concentrations 
for experiments
To identify particular drug-induced cellular 
phenomena without affecting the viability of cells, we 
established a sublethal concentration of each drug. To this 
end, we examined cell viability in GBM-TSs (GSC11, 
TS15-88 and X01) and sphere-cultured U87 GBM cells 
following treatment with HL156A and TMZ, alone 
and in combination, using a 3-(4,5-dimethylthiazol-2-
yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay. HL156A and TMZ at 
concentrations of 15 and 500 μM, respectively, which 
showed minimal effects on cell viability (>80%) in three 
out of the four cell types, were adopted as sublethal 
concentrations for subsequent experiments (Figure 3A). The 
combination treatment was additive, but not synergistic.
Effects of HL156A, TMZ, and combination 
treatment on cellular metabolism of GBM TSs 
and AMPK-mTOR pathway
Given that HL156A was originally developed as an 
AMPK agonist, we assessed the effects of HL156A, TMZ 
and their combination on cellular metabolism by assaying 
ATP, 18F-FDG uptake and oxygen consumption rate 
(OCR) (Figure 3B, 3C, and 3D). Even at a concentration 
that does not affect viability, treatment with HL156A, 
TMZ or their combination decreased ATP levels, 18F-FDG 
uptake and OCR, suggestive of metabolic perturbations in 
cells and energy stress. The decrease was most prominent 
in the combination treatment group. At the concentration 
examined, TMZ alone and in combination with TMZ 
caused a minimal increase in apoptosis, but had no clear 
G2/M-blocking effect; this contrasts with a previous report 
showing that an AMPK agonist blocks G2/M in cells 
(Figure 3E) [16] An examination of GBM-TSs revealed 
inconsistent expression of AMPK-mTOR pathway 
proteins. AMPK phosphorylation and subsequent mTOR 
inhibition in response to the drugs was not observed in 
tested GBM-TSs, despite ATP depletion in these cells 
(Figure 3F). There was no previously known LKB1 gene 
mutation in GSC11 cell line when we analyzed exon 
1,2,3,5 and 7, except one deletion on exon 3 which is not 
described in other disease.
Effects of HL156A, TMZ, and combination 
treatment on the stemness of GBM TSs
HL156, TMZ and combination treatment decreased 
the stemness of GSC11, TS15-88, U87 and X01 TSs, as 
demonstrated by tumorsphere-formation assays (Figure 
4A and 4B) and Western blotting for stemness markers, 
including nestin, CD133, Sox-2, Oct3/4, Notch 2, and 
Twist. The proportion of sphere-positive wells was 
markedly decreased by treatment with HL156A or TMZ 
alone, and was more prominently decreased by combined 
treatment with HL156A and TMZ (Figure 4B). This latter 
effect was additive, although there was a trend towards 
synergy that fell short of significance. LDH assays 
revealed that a majority of sphere cells were viable, 
implying that the decrease in sphere formation is not 
attributable to cell death (Figure 4C). Combined treatment 
with Hl156A and TMZ caused a decrease in Sox2 and 
Notch2 expression in GSC11 TSs, and decreased Oct 3/4, 
Sox2, Notch 2 expression in TS15-88 and X01 TSs (Figure 




GSC11 Classical WT Unmethylation
TS15-88 Classical WT Unmethylation
X01 Mesenchymal N/A* N/A*
TS13-20 Neural WT Methylation
U87 sphere Mesenchymal WT Methylation
N/A* : Assay failed
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Table 2: Blood brain barrier permeability of HL156A
Compound Time Plasma(ng/mL) Brain(ng/g) BP ratio (Cbrain/
Cplasma)
HL156A
0.5 582.67 99.2 0.17
3 172.33 63.07 0.37
Metformin
0.5 583.5 74 0.13
3 534.33 50.13 0.1
Figure 2: The chemical structure and pharmacokinetics of HL156A. A. The structures of HL156A and metformin. HL156A 
contains the central biguanide moiety of metformin. B. Pharmacokinetics of HL156A. The bioavailability of the drug was determined to be 
~72.9% following administration of a dose of 30 mg/kg in mice.
4D). This effect was not attributable to changes in cellular 
viability or cytotoxic effects of drugs, as evidenced by the 
fact that LDH assays also revealed no significant cell death 
in HL156A, TMZ or combined treatment groups (Figure 
4C). Neither HL156A nor TMZ promoted neuro-glial 
differentiation, as evidenced by the absence of a change 
in the expression of the neuronal markers Olig2, Tuj1, 
and GFAP (Supplementary Figure 1). Thus, it is unlikely 
that the therapeutic effect of these agents is mediated 
by differentiation of tumor cells into mature cells—one 
proposed mechanism for targeting CSCs.
Effects of HL156A, TMZ, and combination 
treatment on the invasive properties of GBM 
TSs and marker expression of epithelial 
mesenchymal transition
We evaluated the effect of drugs on the invasive 
property of GBM TSs using three dimensional (3D) matrix 
platforms and quantified the result by assessing the area of 
invasion of GBM TSs. The implanted GBM TS migrated 
radially into the collagen matrix, relevant to in vivo 
tumor behaviors. The treatment with HL156A, TMZ or a 
Oncotarget65648www.impactjournals.com/oncotarget
combination of both drugs suppressed the invasiveness of 
GSC11 GBM TSs compared with controls (Supplementary 
Videos S1 and S2), an effect that was most prominent 
with combination treatment, when assessed quantitatively 
(Figure 5A and 5B, implanted cells and drugs together) 
This invasion-suppressing action was not attributable to 
drug effects on cell viability since cell viability was not 
significantly affected under these experimental conditions. 
To identify mechanisms underlying of inhibition of 
invasion, we assessed expression of the EMT-related 
markers, β-catenin, Zeb1 and N-cadherin, and the 
mesenchymal-epithelial markers E-cadherin and Zo-1. 
These markers showed inconsistent expression among 
cell types, with TMZ and combination treatment causing 
decreased N-cadherin expression in GSC11 cells, and 
decreased Zeb1 and N-cadherin expression in TS15-88 and 
X01 cells; the latter observation may provide a mechanism 
to account for the results of 3D invasion assays described 
above (Figure 5C).
Gene expression microarray and gene ontology 
analysis
Transcriptome analyses was performed using 
Illumina HumanHT-12 v4 Expression BeadChips, and 
a heatmap of top-ranked differentially expressed genes 
Figure 3: Effects of HL156A, TMZ, and combination treatment on cell viability. A. HL156A and TMZ alone, at concentrations 
of 15 and 500uM, respectively, showed minimal effects on cell viability, enabling us to assess the cellular mechanism responsible for the 
effects of HL156A. B. ATP level was decreased on the treatment of HL156A, TMZ and HL156A+TMZ. C. 18F-FDG uptake was markedly 
decreased in GBM-TSs treated with HL156A, TMZ, or both. The decrease in FDG uptake was most prominent in the combination-treatment 
group, suggestive of a low metabolic status. D. Oxygen consumption rate was markedly decreased by treatment with HL156A or TMZ, 
and was prominently observed in the combination treatment group. Similar findings were observed with metformin plus TMZ treatment. 
(Continued )
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was generated (Figure 6). These analyses identified genes 
that were differentially expressed following combination 
treatment. Among several downregulated genes were those 
encoding FBLN7, an adhesion protein that interacts with 
extracellular matrix, Lyn, a protein known to regulate 
cell migration, and LAMA4, a type of laminin. Using a 
BRB-Array tool to perform a Gene Ontology analysis 
of genes that were differentially expressed between 
TMZ alone and combined treatment with HL156A and 
TMZ, we found that the differentially expressed gene set 
included genes related to cell adhesion, cell migration, cell 
motion, and regulation of cell adhesion (Supplementary 
Table 2). Consistent with previous reports that biguanide 
blocks mitochondrial complex I, we found that combined 
treatment with HL156A and TMZ down-regulated several 
genes belonging to mitochondrial complex I. We also 
observed that stemness markers (CD133/PROM1, ZEB1 
and PDPN) were down-regulated whereas E-cadherin 
(CDH2) expression was up-regulated in the combination 
treatment group.
Figure 3 (Continued ): E. Treatment with HL156A or HL156A+TMZ did not cause cell-cycle arrest or definite apoptotic cell death at 
the tested concentration. F. Effects of HL156A, TMZ, and combination treatment on AMPK and the mTOR pathway. Although biguanide 
is known to act as an AMPK agonist and inhibitor of mTOR signaling, neither AMPK activation nor subsequent mTOR inhibition was 
consistently observed, suggesting that AMPK-mTOR is not the major pathway by which HL156A and HL156A+TMZ act.
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Effects of HL156A on xenograft tumor growth
Finally, we analyzed the survival of orthotopic 
xenograft mice. Median survival times of controls and 
mice treated with HL156A, TMZ and HL156A+TMZ (n=5 
per each group) were 47, 82, 58 and 106 days, respectively. 
Separately, bioluminescence images of mice treated with 
drugs were analyzed and quantified (Figure 7A and 7B). 
After sacrificing animals, brains were removed, sectioned, 
and stained with H&E. Although combination treatment 
did not prevent the formation of tumors, it limited the 
size and extent of tumor masses (Figure 7C). As shown 
in Figure 7C, these in vivo experiments revealed that 
combined treatment with HL156A and TMZ exerted a 
significant beneficial effect on the overall survival of 
animals (P < 0.001, log rank test). The survival benefit 
was reproduced at a higher dose of HL156A (45 mg/kg, P 
< 0.001; Supplementary Figure 2).
DISCUSSION
Despite recent progress in our understanding of 
GBM, the prognosis for GBM patients remains grim [17]. 
Even in cases where surgery appears to achieve complete 
resection, the tumor tends to recur and ultimately takes 
the patient’s life [18–20]. Accordingly, a new therapeutic 
strategy would seem to be required. Identifying key 
Figure 4: Effects of HL156A, TMZ, and combination treatment on stemness and neuroglial differentiation of GBM-
TSs. A, B. Effects of HL156A and combination treatment with HL156A and TMZ on stemness were assessed using tumorsphere-formation 
assays (A) and quantified (B), revealing a decrease in the number of neurospheres. C. Cytotoxicity during tumorsphere-formation assays 
was minimal, as evidenced by the results of LDH assays. D. Combination treatment with HL156A and TMZ decreased expression of the 
stemness markers Oct3/4, Sox2, and Notch2.
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Figure 5: Effects of HL156A, TMZ, and combination treatment on the invasive properties of GSC11, TS15-88 
and TS13-20 GBM-TSs, and sphere-cultured U87 and X01 cells. A, B. 3D collagen matrix invasion assays show decreased 
invasiveness of cells implanted together with HL156A or HL156A + TMZ (A), as quantified in B. C. Expression of EMT pathway-related 
markers was altered by treatment with HL156A, TMZ or both, an effect that was most prominent with combination treatment.
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molecules associated with the unique properties of tumor 
cells so as to target these cells may be a viable approach, 
since numerous studies have reported that tumorspheres 
derived from GBM are chemo- and radio-resistant, which 
could potentially cause recurrence of the disease.
In the present study, we examined the effects 
of treatment with HL156A and TMZ, alone and in 
combination, on the stemness and invasive properties of 
GBM TSs (GSC11, TS15-88, TS13-20, U87 sphere and 
X01). Combined treatment with the new agent HL156A 
and the well-known conventional chemotherapeutic agent 
TMZ reduced stemness and invasive properties of GBM-
TSs, an effect that was associated with changes in EMT-
related markers. A similar additive effect of metformin and 
conventional therapy has been reported for a breast cancer 
stem cell model [21] and glioblastoma model [22, 23]. 
The authors of former study reported an additive effect 
of metformin with the cytotoxic effects of hyperthermia 
and showed this was mediated by activation of AMPK and 
inactivation of mTOR [21]. Metformin is also known to 
kill and radiosensitize cancer cells, and to preferentially 
kill breast cancer stem cells, [24] an effect that has 
also been observed in GBM [23]. One group reported 
metformin plus TMZ-based chemotherapy as an adjuvant 
treatment for WHO grade III and IV malignant gliomas, 
[25] and another group specifically targeted CSCs of GBM 
using metformin plus sorafenib [23, 26]. Among possible 
contributors to the superior survival results observed in 
the combination group in the present study are 1) the 
combined actions of the cytotoxic effect of TMZ on 
tumors and the deteriorated cellular energy metabolism 
environment induced by HL156A, and 2) the additive 
inhibitory effect of TMZ and HL156A on the invasive 
properties of TSs, which results in a less aggressive 
Figure 6: High-throughput gene expression microarray. A. Differentially expressed genes between control and the combination 
treatment group. B. Expression of mitochondria complex I genes. Some genes were down-regulated in the combination treatment group. C. 
Expression of selected genes. CD133 (PROM1), podoplanin (PDPN), and ZEB1 were down-regulated in the combination treatment group, 
consistent with the results of Western blot analyses.
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tumor phenotype. Given the heterogeneity of cancer cells, 
targeting GBM CSCs by evoking general metabolic stress 
seems a reasonable approach, as it may provide a less 
favorable environment for metabolically active tumor cells 
[27, 28]. Although the well-known biguanide, metformin, 
may have effects similar to those of HL156A, the delivery 
of metformin to the brain is limited [29]. HL156A 
overcomes this shortcoming and shows generally high 
bioavailability. The prominent survival benefit of in vivo 
combination treatment may be attributable to the excellent 
penetration ability of HL156A. Further studies on this new 
compound in combination with conventional therapy in 
the treatment of malignant tumors are warranted.
The cellular mechanism underlying the effect of 
HL156A on GBM seems distinct in that the expected 
AMPK activation and consequent inhibition of the mTOR 
pathway was not consistently observed in this study. It 
was reported that cellular sensitivity to metformin also 
depends on the genetic and mutational backgrounds of the 
different GB cells [23]. Thus, different genetic background 
of GSC11 TSs and X01 TSs may explain this discrepancy 
in the response of those specific pathway. Recently, Liu 
Figure 7: Effects of HL156A and combined HL156A and TMZ treatment on xenograft tumor growth and animal 
survival. A, B. GSC11-luc TSs were xenografted and tumors from animals treated with HL156A (35 mg/kg) or TMZ (30 mg/kg) alone, 
or HL156A and TMZ (45 and 30 mg/kg, respectively) in combination were assessed using bioluminescence imaging (n=5 for each group) 
Tumor volumes were assessed and quantified. C. Tumors from animals treated with HL156A or HL156A and TMZ showed less irregular 
margins than those from controls. Notably, combination treatment decreased tumor volume. Survival of animals in the combination 
treatment group was significantly increased (P < 0.0001).
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et al. reported that AMPK is activated in glioblastoma, 
and the anti-proliferative effect of metformin is AMPK 
independent [16]. The present study also confirmed 
increased basal AMPK expression in GSC11 and X01 
cells, and similarly, found that AMPK activation and 
consequent mTOR inhibition apparently underlie the 
inhibitory effect of HL156A and the combination of 
HL156A and TMZ on GBM TSs. Instead, HL156A, 
whether alone or combined with TMZ, compromises 
glucose uptake, as evidenced by the reduced uptake of 
18F-FDG following drug treatment; this contrasts with 
activation of AMPK, which usually leads to an increase 
in glucose uptake [30]. It has been postulated that certain 
types of glioma stem cells are maintained by an activated 
glycolytic metabolism [31], and glycolytic glioma cells 
with active glycogen synthase are further proposed to 
be sensitive to inhibitors of gluconeogenesis such as 
metformin [27]. It has been suggested that metformin 
suppresses gluconeogenesis by inhibiting mitochondrial 
glycerophosphate dehydrogenase [32]. Metformin also 
impairs glycolysis by inhibiting hexokinase II [33]. 
Similarly, the effects of HL156A and the combination of 
HL156A and TMZ on TSs by can be explained by their 
inhibitory effects on intracellular glucose metabolism, 
probably through targeting both mitochondrial and 
glycolytic pathways. As previous studies revealed 
CSCs usually showed less OCR compared with their 
differentiated progenitors [34], the loss of stemness by 
HL156A, TMZ and combination treatment may affect the 
reduction in OCR.
Another unique aspect of the current work is 
that the inhibitory effect of HL156A on the invasive 
properties of GBM TSs may be related to alterations 
of EMT-related markers. Several groups have reported 
that EMT-related markers are upregulated in GBM, and 
shown that acquisition of mesenchymal traits by cancer 
cells undergoing EMT is related to the acquisition of 
a stem cell program [35, 36]. At this point, evidence 
supporting a role for the EMT pathway in the pathogenesis 
of GBM expansion and invasion is not robust. Although 
the process of GBM invasion shares certain similarities 
with that of immature neuron migration during embryonic 
development, little is known about the process, and 
direct evidence for a relation between EMT and invasive 
properties is still lacking [35]. Nevertheless, several lines 
of evidence suggest that similar molecular alterations 
occur with GBM pathophysiology; thus, the effects of 
inhibiting this pathway need to be studied to identify the 
role of this pathway in the invasive properties of this fatal 
disease. An inhibitory effect of metformin on the migration 
of the U87 glioma cell line has been reported [27]. Similar 
experiments targeting the EMT pathway using an RNA 
interference (RNAi) strategy (siRNA or shRNA) may help 
resolve these unanswered questions.
Even among TMZ-responsive patients, death 
ultimately ensues owing to relapse of the disease [1]. 
Several strategies have been proposed for overcoming 
therapeutic limitation of GBMs, but none has yet proved 
successful [17–19]. Because of the intrinsic tendency of 
the tumor to infiltrate into normal brain tissue, complete 
surgical resection would appear to be an unattainable goal 
[37]. Thus, appropriate adjuvant therapy for the potential 
remaining cancer cells, including CSCs, is crucial to 
overcoming the inevitable fate of the disease. Targeting 
GBM TSs as a new strategy needs to be extensively 
evaluated in this context. A caveat to applying this 
concept is the limited information regarding the identity 
of GBM-specific stem cells, which makes it a challenge to 
sort these cells for experimentation. For example, which 
surface markers define CSCs is a matter of controversy 
[38]. Furthermore, some properties of GBM can be 
explained by the clonal evolution model of the disease, 
which provides another axis of tumor heterogeneity 
[39]. Heterogeneity defined by the spatial structure of a 
tumor is better explained by the clonal evolution model. 
A combined model has also been suggested; thus, more 
evidence is needed to understand this specific aspect of the 
disease. Altering general intracellular energy metabolism 
seems to be a reasonable therapeutic strategy since both 
models predict that this approach could effectively target 
neoplastic cells [28]. Accordingly, the use of the newly 
developed agent, HL156A, combined with conventional 
TMZ for targeting GBM CSCs, holds promise as a new 
line of therapy against the disease.
MATERIALS AND METHODS
In vivo blood brain barrier permeability
ICR mice (Saeronbio, Uiwang, Korea) were used 
for pharmacokinetic studies. The blood-brain barrier 
permeability of HL156 and the bioavailability of orally 
administered drug(30 mg/kg) were assessed by injecting 
mice intraperitoneally with HL156A (10 mg/kg) and 
evaluating the concentration of drug in the plasma and 
brain by liquid chromatography-mass spectrometry.
GBM TS culture
The GBM TS cell line GSC11, TS13-20 and 
TS15-88 derived from primary GBM specimens using a 
previously described method [4, 40] (GSC11 was provided 
by Frederick F. Lang, M. D. Anderson Cancer Center, 
Houston, Texas, USA) and the X01 line, derived from a 
female glioblastoma patient, were used for experiment 
[41]. For spheres culture, all GBM TSs (GSC11, X01 
sphere) were cultured in TS complete media composed 
of Dulbecco’s Modified Eagle Medium/Nutrient Mixture 
F-12 (DMEM/F-12; Mediatech, Manassas, VA, USA) 
containing B27 supplements (1×; Invitrogen, San 
Diego, CA, USA), 20 ng/ml of basic fibroblast growth 
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factor (bFGF; Sigma, St. Louis, MO, USA), 20 ng/ml 
of epidermal growth factor (EGF; Sigma), and 50 U/ml 
penicillin/50 mg/ml streptomycin [40, 42, 43].
Lentiviral vector transduction and expression
GSC11 cells stably expressing green fluorescent 
protein (GFP-GSC11) and lucerferase(GFP-luc) were 
generated by growing cells in complete medium and 
then applying supernatants containing GFP/luciferase-
expressing lentivirus. Polybrene (Sigma, Dorset, UK) 
was added to a final concentration of 8 μg/ml and 
incubated with cells for 18 hours. After infection, the 
cells were placed in fresh growth medium and cultured 
using standard methods. Stable GFP/luciferase-GSC11 
cells were selected by culturing with 1 mg/ml puromycin 
(Life Technologies Korea, Seoul, Korea), and isolated 
by fluorescence-activated cell sorting (FACS) for use in 
further experiments.
Cell viability assay
Effects of HL156A, TMZ, and combined 
HL156A and TMZ treatment on cell survival was 
determined using MTS [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt] assays [44]. Briefly, GBM TS 
cells (5 × 103) were seeded in 96-well plates, incubated at 
37°C for 24 hours, and then treated with HL156A, TMZ, 
or both for 5 days. MTS reagent (20 μl/well) was added 
and absorbance was measured at 490 nm after incubating 
at 37°C for 4 hours. Each experiment was repeated three 
times in triplicate, and the results were expressed as the 
percentage of viable cells relative to controls.
Western blotting
An equal amount of total protein from each sample 
(20 μg) in Laemmli sample buffer (GeneTex, Irvine, CA, 
USA) was heated at 100°C for 5 minutes, then resolved by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) on 8% gels and electroblotted onto 
nitrocellulose membranes (GE Healthcare life-Sciences). 
Membranes were blocked in Tris-buffered saline 
containing 0.1% Tween-20 (TBS-T) and 5% non-fat dry 
milk, and incubated overnight at 4°C with antibodies for 
AMPK-mammalian target of rapamycin (mTOR) pathway-
related proteins, stemness markers and EMT-related 
markers, and then probed with peroxidase-conjugated goat 
anti-rabbit IgG (1:2000; Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA) for 1 hour at room temperature. 
After repeated washing, membranes were developed using 
enhanced chemiluminescent (ECL) reagents (Amersham 
Life Science, Inc., Piscataway, NJ, USA). Band densities 
were measured using TINA imaging software (Raytest, 
Straubenhardt, Germany).
Glioma tumorsphere-formation assay
After producing a single-cell suspension, GBM-
TSs (GSC11, TS13-20, TS15-88, U87 sphere and X01) 
were cultured in 96-well plates in medium consisting 
of DMEM/F-12 containing 2% 1× B27 supplements, 
20 ng/ml of 0.02% bFGF, 20 ng/ml of 0.02% EGF, 
and 1% antibiotic–antimycotic solution (100×; Gibco, 
Invitrogen Korea, Seoul, South Korea). The number of 
sphere-positive wells was counted, and the proportion 
of sphere-positive wells in the treatment group relative 
to that in controls was calculated and presented as a 
percentage. Cells cultured under different conditions for 
3 weeks were observed with an inverted phase-contrast 
microscope (I×71 Inverted Microscope; Olympus, Tokyo, 
Japan) to determine TS morphology and size, and imaged 
with a digital camera (DP70 Digital Microscope Camera; 
Olympus) using DP Controller software (Olympus).
Three-dimensional invasion assay
GFP-GSC11, GFP-TS13-20, GFP-TS15-88, 
GFP-U87 sphere and GFP-X01 cells grown as 
spheroids were cultured in collagen I matrices using 
polydimethylsiloxane (PDMS)-based microwells 
(diameter and depth of microwells: 6 mm × 500 μm). 
Microwells were treated with 1% poly(ethyleneimine) 
(Sigma-Aldrich, St. Louis, MO, USA) solution for 10 
minutes followed by 0.1% glutaraldehyde (Sigma-Aldrich) 
for 30 minutes, and then washed overnight with phosphate 
buffered saline (PBS) to make PDMS wells adherent to 
collagen. Collagen I matrices were prepared from high-
concentration rat tail collagen I (BD Bioscience, Le Pont 
de Claix, France) as recommended by the manufacturer. 
Briefly, the appropriate amounts of 10x PBS, 1N NaOH, 
sterile distilled H2O, and collagen I were mixed to create 
gels with the desired final concentration. The solution 
was mixed well and kept at 4°C before use. GFP-GSC11 
spheroids were encapsulated by pipetting 10 μl of collagen 
I solution (4 mg/ml) into the microwell, placing a single 
GFP-GSC11 spheroid from the culture plate onto collagen 
I matrices, and then dropping 10 μl of collagen I solution 
(4 mg/ml) onto the GFP-GSC11 spheroid. The platform 
was incubated at 37°C and 5% CO2 for 30 minutes. Cell 
viability was assessed by staining GFP-GSC11 spheroids 
with 8 μM ethidium homodimer-1 (Invitrogen Korea, 
Seoul, Korea) for 30 minutes at 37°C before implantation 
in collagen matrix. After full gelation, culture medium 
which is consisted of DMEM/F-12 containing 2% 1× 
B27 supplements, 20 ng/ml of 0.02% bFGF, 20 ng/ml 
of 0.02% EGF, and 1% antibiotic–antimycotic solution 
(100×; Gibco) was then added. Cell viability was assessed 
by staining GFP-GSC11 spheroids with 8 μM ethidium 
homodimer-1 (Invitrogen Korea, Seoul, Korea) for 30 
minutes at 37°C after implantation in collagen matrix. 
Drug effects were assessed by mixing drugs with medium 
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to the final desired concentration of each drug. The 
dynamic morphology of GFP-GSC11 spheroids was 
monitored by obtaining images using an inverted laser-
scanning confocal microscope (Nikon Ti-E; Tokyo, 
Japan). Invasiveness was quantified using the maximal 
area covered by migrating edges of cells as a parameter, 
calculated as (invaded area at a certain time/spheroid area 
at initial time) × 100. Data were analyzed using ImageJ 
image analysis software (NIH, Bethesda, MD, USA).
LDH assay
Cytotoxicity was assessed by measuring LDH 
released into culture media. Cells were plated in 96-well 
plates at a density of 10 cells per well. After 24 h, cells 
were treated with 2DG (4 mM), metformin (5 mM or 15 
mM), a combination of 2DG (4 mM) and metformin (5 
mM) for 3 weeks. The amount of LDH in the medium 
was determined using a CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega, Fitchburg, WI, USA) 
according to the manufacturer's instructions. 10μl of Lysis 
Solution (10X) per 100μl of medium was added to each 
well followed by incubation for 45 minutes in a humidified 
chamber at 37°C, 5% CO2. After centrifuge of the plate at 
250 × g for 4 minutes, 50μl aliquots were transferred to a 
fresh 96-well flat-bottom (enzymatic assay) plate. After 
adding 50μl of the reconstituted Substrate Mix, the plate 
was covered with foil to protect it from light, incubated 
at room temperature for 30 minutes, followed by the 
addition of 50μl of Stop Solution. Absorbance at 490 nm 
was determined using a microplate reader.
ATP assay
For the comparison of ATP levels in TS, the 
CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, Fitchburg, WI, USA) was used. Cells were 
plated in 96-well plates at a density of 5 × 103 cells per 
well. After 24 h, they were treated with 4 mM of 2DG, 5 
mM of metformin alone, their combination or 15 mM of 
metformin for 3 days. ATP assay was conducted according 
to the manufacturer’s protocol. A volume of CellTiter-
Glo® Reagent equal to the volume of cell culture medium 
present in each well was added. Cells were incubated at 
room temperature for 10 minutes, and luminescence was 
recorded.
Uptake of 18F-FDG
GSC11 cells were plated on 12-well plates at 3 × 105 
cells per well, and incubated for 24 hours. The medium 
was changed to glucose-free DMEM (Gibco) containing 
approximately 0.5 μCi of 18F-fluorodeoxyglucose 
(18F-FDG), and then cells were incubated for 15 minutes. 
The cells were washed three times with PBS, and 0.1 ml 
of lysis buffer was added to each well. The lysed cells 
were then harvested, and the amount of radioactivity 
in lysates was measured using a Wallac 148 Wizard 3 
gamma-counter (PerkinElmer Life and Analytical Science, 
Shelton, CT, USA) and normalized to protein content.
Gene expression microarray and gene ontology 
analysis
Total RNA was extracted from 100 mg of GBM-TSs 
using a Qiagen miRNA kit according to the manufacturer’s 
protocol. Expression profiles of drug-treated groups and 
controls were obtained using Illumina HumanHT-12 
v4 Expression BeadChips (Illumina, Inc., San Diego, 
CA, USA). Data were log2 transformed and normalized 
according to the quantile normalization method using 
BRB-ArrayTools developed by Dr. Richard Simon and 
the BRB-ArrayTools Development Team. Genes showing 
minimal variation across the set of arrays were excluded 
from the analysis. Genes whose expression differed from 
the median by at least 1.5-fold in at least 20% of the 
arrays were retained. Heatmaps were generated and gene 
ontology analyses were performed using BRB-ArrayTools 
and GENE-E from broad institute.
Orthotopic xenograft animal model for the 
assessment of survival
Male athymic nude mice (4–8 weeks old; Central 
Lab. Animal Inc., Seoul, Korea) were used for experiments. 
Mice were housed in micro-isolator cages under sterile 
conditions and observed for at least 1 week before study 
initiation to ensure proper health. Lighting, temperature, 
and humidity were controlled centrally. All experimental 
procedures were approved by our Institutional Animal 
Care and Use Committee. Mice were anesthetized with 
a solution of Zoletil (30 mg/kg; Virbac Korea, Seoul, 
Korea) and xylazine (10 mg/kg; Bayer Korea, Seoul, 
Korea) delivered intraperitoneally. GBM TSs (GSC11) 
were implanted into the right frontal lobe of nude mice 
using a guide-screw system within the skull. Mice 
received 5 × 105 cells via a Hamilton syringe (Dongwoo 
Science Co., Seoul, Korea) inserted to a depth of 4.5 mm. 
Then, HL156A (30 or 45 mg/kg), TMZ (30 mg/kg), their 
combination, metformin(500 mg/kg) and metformin and 
TMZ combination were administrated to mice (n = 5 mice/
group). HL156A and metformin was administered orally 
every other day throughout the duration of the experiment, 
and TMZ was administrated intraperitoneally for 5 days 
beginning the day of TS injection. The body weights of 
mice were checked every other day. If weight decreased 
by more than 15% compared to the original body weight, 
mice were euthanized according to the approved protocol. 
At the end of the experiment, mice were euthanized and 
their brains were carefully removed, sectioned, mounted 
on glass slides and stained with hematoxylin and eosin 
(H&E) for microscopic analysis of gliomagenesis.
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Bioluminescence imaging of animal for the 
asssement of tumor volume
Bioluminescence acquisition and analysis were 
performed with the IVIS Imaging System and Living 
Image V4.2 software. GSC-luc animals were generated 
as previously described [22] and injected intraperitoneally 
with d-luciferin (30 mg/mL DPBS, 100mL) at 15 min 
prior to signal acquisition (5 seconds), which took place 
under 2.5% isoflurane anesthesia. Grayscale photographic 
images and bioluminescence color images were 
superimposed.
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). Student’s 
t-test or Mann–Whitney U test was used for comparison 
of mean viability and FDG uptake of agent by treated 
cells. Two-way analysis of variance (ANOVA) was used 
to detect synergistic effects of combination treatment. 
Kaplan–Meier survival curves and log-rank statistics 
were employed for survival analyses. P-values < .05 were 
considered statistically significant.
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